Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডKyle Diamantas 52%
No announcement by December 31 13.9%
Stephen Hahn 4%
Brett Giroir 3.9%
নতুন
নতুন
Dec 31, 2026
Kyle Diamantas
52%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
14%
Kyle Diamantas 52%
No announcement by December 31 13.9%
Stephen Hahn 4%
Brett Giroir 3.9%
নতুন
নতুন
Dec 31, 2026
Kyle Diamantas
$1,525 Vol.
52%
Stephen Hahn
$976 Vol.
4%
Brett Giroir
$1,510 Vol.
4%
Grace Graham
$1,893 Vol.
3%
Sara Brenner
$849 Vol.
3%
No announcement by December 31
$533 Vol.
14%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 12, 2026, 7:59 PM ET
ভলিউম
$7,286শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ভলিউম
$7,286শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা